Amicus Therapeutics Announces Second Quarter 2023 Financial Results and Corporate Updates
Provided By GlobeNewswire
Last update: Aug 8, 2023
1H 2023 Revenue Growth of 16% at CER to $180.8M
Raising FY 2023 Galafold® Revenue Growth Guidance to 14%-18% at CER
Read more at globenewswire.com
